The association of rs3129859 was robust in ACLF subgroups (ACLFs with liver cirrhosis, p=1.36×10<sup>-16</sup>; ACLFs without liver cirrhosis, p=1.52×10<sup>-7</sup>), and patients at low-replicative phase (p=6.36×10<sup>-11</sup>, OR=2.29) or HBV e antigen-negative chronic hepatitis B phase (p=1.51×10<sup>-14</sup>, OR=1.86).
Among 1300 ACLFs and 2087 AsCs, we identified r</span>s3129859 at human leucocyte antigen (HLA) class II region (chromosome 6p21.32) associated with HBV-related ACLF (combined P <i>
A C>T mutation in SNP rs7308855 and a T>A mutation in SNP rs7298346 showed an association with the presence of coagulation failure in the entire population (n=61, P=0.024 and 0.060, respectively) and in the subgroup of patients with ACLF (n=44, P=0.081 and 0.056, respectively).
A C>T mutation in SNP rs7308855 and a T>A mutation in SNP rs7298346 showed an association with the presence of coagulation failure in the entire population (n=61, P=0.024 and 0.060, respectively) and in the subgroup of patients with ACLF (n=44, P=0.081 and 0.056, respectively).
The p.Ser267Phe NTCP variant is significantly associated with resistance to chronic hepatitis B and a lower incidence of acute-on-chronic liver failure.
These results indicate that TLR3 C1234T polymorphism could be a risk factor for the development of chronic HBV infection, especially the CHB-related ACLF.